TABLE 4.
Baseline characteristics and outcomes of patients with cystic fibrosis stratified by intermittent or chronic Achromobacter xylosoxidans isolation
| Characteristics or outcomes | Intermittent (n=13) | Chronic (n=23) | p-value |
| Baseline characteristics | |||
| Female | 6 (46.2) | 13 (56.5) | 0.55 |
| Age at Achromobacter xylosoxidans detection years | 28.0 (26.0–36.0) | 21.0 (19.0–28.0) | 0.019 |
| Weight kg | 63.0 (47.0–67.0) | 49.0 (44.0–56.0) | 0.032 |
| BMI kg·m−2 | 21.1 (17.8–22.4) | 18.7 (17.6–20.1) | 0.052 |
| Homozygous F508del | 6 (46.2) | 8 (38.1) | 0.64 |
| Pancreatic insufficiency | 11 (84.6) | 19 (82.6) | 1.00 |
| Diabetes | 2 (15.4) | 9 (39.1) | 0.26 |
| Azithromycin | 2 (15.4) | 12 (52.2) | 0.030 |
| Pseudomonas aeruginosa isolation | 10 (76.9) | 17 (73.9) | 1.00 |
| Allergic bronchopulmonary aspergillosis | 6 (46.2) | 12 (52.2) | 0.73 |
| FEV1 the year before Achromobacter xylosoxidans detection % | 58.0 (30.0–75.0) | 49.0 (31.0–77.0) | 1.00 |
| Pseudomonas aeruginosa antibiotic courses in year before baseline | 2.0 (1.0–3.0) | 3.0 (2.0–5.0) | NA |
| Outcomes | |||
| Lung function | |||
| ΔFEV1 %·year−1 | −3.82±1.16 | −5.55±0.52 | 0.17 |
| ΔFEV1 mL·year−1 | −135.9±38.56 | −157.2±17.96 | 0.62 |
| Number of exacerbations: | |||
| Year before baseline | 1.0 (1.0– 3.0) | 3.0 (2.0–4.0) | 0.066 |
| Year after baseline | 2.0 (1.0–4.0) | 3.0 (2.0–4.0) | 0.22 |
| Years 1 and 2 after baseline# | 4.0 (3.0–6.0) | 7.0 (5.0–9.0) | 0.049 |
| Years 1–3 after baseline# | 6.0 (4.0–6.0) | 9.5 (7.5–13.0) | 0.012 |
Data are presented as n (%), median (interquartile range) or β±se (slope of change calculated from the baseline (time of bacterial detection)), unless otherwise stated. BMI: body mass index; FEV1: forced expiratory volume in 1 s. #: Cumulative number of exacerbations.